Sensitive Malignancy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sensitive malignancy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sensitive Malignancy Today - Breaking & Trending Today

New Efficacy Data Reinforces NEXTSTELLIS® Benefits Across Patient Populations

New Efficacy Data Reinforces NEXTSTELLIS® Benefits Across Patient Populations
Results presented at the 2021 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting
News provided by
Share this article
Share this article
GREENVILLE, N.C., April 30, 2021 /PRNewswire/ Mayne Pharma announced today results from two studies showing treatment with NEXTSTELLIS® (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets) demonstrated contraceptive efficacy and excellent cycle control across subgroups, including age, body mass index (BMI)[1] and prior contraceptive use. NEXTSTELLIS is the first contraceptive pill containing E4, a new naturally occurring estrogen with a unique mechanism of action that offers potential advantages over other estrogens. The findings were presented at the 2021 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting, held virtually in the U.S. from April 30 – Ma ....

United States , Mashonaland East , Mayne Pharma , Prnewswire Mayne Pharma , Estetrol Drospirenone , Karen Dombek , Mitchell Creinin , University Of California , Mayne Pharma Group , American College Of Obstetricians , Women Health , Annual Clinical , Scientific Meeting , Family Planning , Pearl Index , Subgroup Analysis , Pregnancy Prevention , Canadian Phase , Prescribing Information , Sensitive Malignancy , Full Prescribing Information , Mayne Pharma Group Limited , ஒன்றுபட்டது மாநிலங்களில் , மஷோனலண்ட் கிழக்கு , மேனே பார்மா , கரேன் தொம்பேக் ,

U.S. FDA Approves NEXTSTELLIS®, New Oral Contraceptive

GREENVILLE, N.C., April 16, 2021 /PRNewswire/ Â Mayne Pharma announced today that the U.S. Food and Drug Administration (FDA) has approved NEXTSTELLIS (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets) for the prevention of pregnancy. NEXTSTELLIS is the first and only contraceptive pill containing E4, a naturally occurring estrogen, now produced from a plant source, with a unique mechanism of action that offers potential advantages over other estrogens.
When speaking with patients about their contraceptive options, one of the most common concerns is side effects, said Mitchell Creinin, Professor and Director of Family Planning at the University of California, Davis. NEXTSTELLIS is an innovative contraceptive that has been shown to be not only safe and effective, but also well tolerated in clinical trials with a desirable bleeding profile and minimal impact on triglycerides, cholesterol, and glucose, as well as weight and endocrine markers. ....

United States , Mashonaland East , Scott Richards , Mayne Pharma , Mitchell Creinin , Mithra Pharmaceuticals , University Of California , Mayne Pharma Group , Women Health , Drug Administration , Family Planning , Native Estrogen , Prescribing Information , Sensitive Malignancy , Full Prescribing Information , Mayne Pharma Group Limited , Laura De Zutter , North Carolina , United States Of America , North America , Oral Contraceptive , Mayne Pharma Group Limited , Breakthrough Bleeding , ஒன்றுபட்டது மாநிலங்களில் , மஷோனலண்ட் கிழக்கு , ஸ்காட் ரிச்சர்ட்ஸ் ,

U.S. FDA Approves NEXTSTELLIS®, New Oral Contraceptive

U.S. FDA Approves NEXTSTELLIS®, New Oral Contraceptive
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Mashonaland East , Scott Richards , Mayne Pharma , Mitchell Creinin , Mithra Pharmaceuticals , University Of California , Mayne Pharma Group , Women Health , Drug Administration , Family Planning , Prescribing Information , Sensitive Malignancy , Full Prescribing Information , Mayne Pharma Group Limited , Laura De Zutter , ஒன்றுபட்டது மாநிலங்களில் , மஷோனலண்ட் கிழக்கு , ஸ்காட் ரிச்சர்ட்ஸ் , மேனே பார்மா , மித்ரா மருந்துகள் , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா , மேனே பார்மா குழு , பெண்கள் ஆரோக்கியம் , குடும்பம் திட்டமிடல் , ப்ரிஸ்க்ரைபிஂக் தகவல் ,

U.S. FDA Approves NEXTSTELLIS®, New Oral Contraceptive

U.S. FDA Approves NEXTSTELLIS®, New Oral Contraceptive
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Mashonaland East , Scott Richards , Mayne Pharma , Mitchell Creinin , Mithra Pharmaceuticals , University Of California , Mayne Pharma Group , Women Health , Drug Administration , Family Planning , Prescribing Information , Sensitive Malignancy , Full Prescribing Information , Mayne Pharma Group Limited , Laura De Zutter , ஒன்றுபட்டது மாநிலங்களில் , மஷோனலண்ட் கிழக்கு , ஸ்காட் ரிச்சர்ட்ஸ் , மேனே பார்மா , மித்ரா மருந்துகள் , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா , மேனே பார்மா குழு , பெண்கள் ஆரோக்கியம் , குடும்பம் திட்டமிடல் , ப்ரிஸ்க்ரைபிஂக் தகவல் ,